Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma
- 1 October 1998
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 352 (9134), 1109-1113
- https://doi.org/10.1016/s0140-6736(97)12261-9
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Current best practice for nebuliser treatment. British Thoracic Society Nebulizer Project Groupx [published erratum appears in Thorax 1997 Sep;52(9):838]Thorax, 1997
- Secretion of the eosinophil‐active cytokines interleukin‐5, granulocyte/macrophage colonystimulating factor and interleukin‐3 by bronchoalveolar lavage CD4+ and CD8+ T cell lines in atopics asthmatics, and atopic and nonatopic controlsEuropean Journal of Immunology, 1995
- Treatment with anti‐cd4 monoclonal antibody and acute interstitial nephritisArthritis & Rheumatism, 1993
- Activated memory T helper cells in bronchoalveolar lavage fluid from patients with atopic asthma: relation to asthma symptoms, lung function, and bronchial responsiveness.Thorax, 1993
- “Primatization” of Recombinant Antibodies for Immunotherapy of Human Diseases: A Macaque/Human Chimeric Antibody Against Human CD4Nature Biotechnology, 1992
- Activated T cells and eosinophilia in bronchoalveolar lavages from subjects with asthma correlated with disease severityJournal of Allergy and Clinical Immunology, 1991
- Anti-CD4 therapy of acute rejection in long-term renal allograft recipientsThe Lancet, 1991
- Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasisThe Lancet, 1991
- Human eosinophils express CD4 protein and bind human immunodeficiency virus 1 gp120.The Journal of Experimental Medicine, 1989
- MONOCLONAL ANTI-CD4 IN ARTHRITISThe Lancet, 1987